High Expression of DEPDC1B Predicts Poor Prognosis in Lung Adenocarcinoma

Figures & data

Figure 1 DEPDC1B expression in lung adenocarcinoma (LUAD). (A) DEPDC1B expression levels in LUAD and normal tissues from a TCGA dataset. (B) DEPDC1B expression levels in LUAD and paired normal tissues from a TCGA dataset. (C) Immunohistochemical staining of DEPDC1B in LUAD and adjacent normal lung tissues from 100 patients. Representative IHC images of DEPDC1B expression in normal tissues (D) and LUAD tissues (E).

Abbreviations: DEPDC1B, DEP domain-containing 1 B; TCGA, The Cancer Genome Atlas; IHC, immunohistochemistry.

Figure 2 Association of DEPDC1B expression with clinicopathologic characteristics in lung adenocarcinoma (LUAD): (A) T stage, (B) N stage, (C) primary therapy outcome, (D) pathologic stage, (E) gender, (F) age, and (G) smoker.

Abbreviations: DEPDC1B, DEP domain-containing 1 B; LUAD, lung adenocarcinoma.

Figure 3 Kaplan-Meier survival curves comparing patients with high and low DEPDC1B-expressing LUAD from a TCGA dataset. (A) Overall survival and (B) progression free interval. Kaplan–Meier survival curves of 100 LUAD patients with high and low DEPDC1B-expressing tumors (C) Overall survival and (D) progression free interval.

Abbreviations: DEPDC1B, DEP domain-containing 1 B; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas.

Figure 4 Relationship between DEPDC1B expression and different clinicopathological factors with overall survival. (A) Survival analysis of different clinical subgroups of patients with LUAD according to DEPDC1B expression. (B) Nomogram for predicting the outcome of patients with LUAD.

Abbreviations: DEPDC1B, DEP domain-containing 1 B; LUAD, lung adenocarcinoma.

Table 1 Correlations Between DEPDC1B Expression and Overall Survival in Patients with Lung Adenocarcinoma Based on Univariate and Multivariate Cox Regression Analysis

Characteristics	Total (N)	Univariate Analysis HR (95% CI)	P value	Multivariate Analysis HR (95% CI)	P value
T stage	523	2.317 (1.591–3.375)	<0.001	1.706 (0.928–3.136)	0.085
T1 & T2	457
T3 & T4	66
N stage	510	2.601 (1.944–3.480)	<0.001	1.809 (1.159–2.824)	0.009
N0	343
N1, N2, and N3	167
M stage	377	2.136 (1.248–3.653)	0.006	1.219 (0.501–2.962)	0.662
M0	352
M1	25
Age	516	1.223 (0.916–1.635)	0.172
≤65	255
>65	261
Gender	526	1.070 (0.803–1.426)	0.642
Female	280
Male	246
Smoker	512	0.894 (0.592–1.348)	0.591
No	72
Yes	440
Pathologic stage	518	2.664 (1.960–3.621)	<0.001	1.455 (0.795–2.663)	0.224
I & II	411
III & IV	107
Primary therapy outcome	439	0.372 (0.265–0.521)	<0.001	0.366 (0.243–0.551)	<0.001
PD, SD, and PR	113
CR	326
Race	468	1.475 (0.902–2.411)	0.121
Asian & Black or African American	62
White	406
DEPDC1B	526	1.713 (1.276–2.300)	<0.001	1.949 (1.292–2.940)	0.001
Low	265
High	261

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response.

Table 2 Univariate and Multivariate Analyses of Overall Survival and Progression Free Interval in 100 Patients with Lung Adenocarcinoma

Clinical Characteristics	OS				PFI
	Univariate Analysis		Multivariate Analysis		Univariate Analysis		Multivariate Analysis
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age (years)	0.848 (0.472–1.522)	0.580			0.884 (0.492–1.586)	0.678
≤65
>65
Gender	0.328 (0.167–0.646)	0.001	0.322 (0.160–0.650)	0.002	0.324 (0.165–0.638)	0.001	0.318 (0.157–0.642)	0.001
Male
Female
Smoker	0.677 (0.304–1.510)	0.341			0.714 (0.320–1.592)	0.410
Ever
Never
T stage	1.748 (0.908–3.366)	0.095			1.813 (0.942–3.489)	0.075
T1 & T2
T3 & T4
N stage	1.954 (1.105–3.457)	0.021	1.088 (0.594–1.990)	0.786	2.037 (1.151–3.606)	0.015	1.210 (0.648–2.260)	0.549
N0
N1, N2, and N3
M stage	2.353 (0.998–5.547)	0.050			2.372 (1.005–5.598)	0.049	1.530 (0.540–4.332)	0.423
M0
M1
Pathologic stage	3.065 (1.716–5.474)	<0.001	2.105 (1.135–3.907)	0.018	3.304 (1.841–5.931)	<0.001	2.089 (1.028–4.246)	0.042
I & II
III & IV
Differentiation	2.147 (1.210–3.808)	0.009	2.735 (1.494–5.005)	0.001	2.225 (1.253–3.952)	0.006	2.922 (1.597–5.347)	<0.001
Well & moderate
Poor
DEPDC1B expression	4.706 (2.319–9.547)	<0.001	3.564 (1.737–7.311)	<0.001	4.583 (2.261–9.291)	<0.001	3.609 (1.754–7.425)	<0.001
Low
High

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; OS, overall survival; PFI, progression free interval; DEPDC1B, DEP domain-containing 1 B.

Figure 5 Differentially expressed genes between patients with high and low DEPDC1B-expressing LUAD. (A) Volcano plot of differentially expressed genes according DEPDC1B expression status. (B) Heat map showing 10 upregulated and downregulated genes selected based on DEPDC1B expression status. (Pearson). GO enrichment analysis of DEPDC1B expression-related genes. (C) Enriched GO biological process terms. (D) Enriched GO cellular component terms. (E) Enriched GO molecular function terms. *P < 0.05; **P < 0.01; ***P < 0.001.

Abbreviations: DEPDC1B, DEP domain-containing 1 B; LUAD, lung adenocarcinoma; GO, Gene Ontology.

Figure 6 Enrichment plot from gene set enrichment analysis (GSEA). (A) Retinoblastoma gene in cancer, (B) cell cycle checkpoints, (C) PLK1 pathway, (D) mitotic spindle checkpoint, (E) deposition of new CENP-A-containing nucleosomes at the centromere, (F) meiotic recombination, (G) DNA replication, and (H) resolution of sister chromatid cohesion.

Abbreviation: PLK1, Polo-like kinase 1.

Figure 7 Correlations between immune cell infiltration and DEPDC1B expression levels in LUAD. (A) Relationship between DEPDC1B expression and infiltration of 24 immune cell types. Relationship between DEPDC1B expression and infiltration of (B) mast cells, (C) eosinophils, (D) iDCs, (E) TFHs, (F) Th2 cells, and (G) Tgd cells.

Abbreviations: DEPDC1B, DEP domain-containing 1 B; LUAD, lung adenocarcinoma; iDCs, immature dendritic cells; TFHs, follicular helper T cells; Th2, type-2 T helper; Tgd, gamma delta T.